<DOC>
	<DOCNO>NCT01973335</DOCNO>
	<brief_summary>This study two primary objective : 1 . To compare combination therapy acetazolamide low-dose loop diuretic versus high-dose loop diuretic ( standard care ) patient acute decompensated heart failure high risk diuretic resistance . 2 . To demonstrate safety efficacy upfront therapy spironolactone addition loop diuretic therapy patient acute decompensated heart failure high risk diuretic resistance .</brief_summary>
	<brief_title>Acetazolamide Spironolactone Increase Natriuresis Congestive Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<mesh_term>Acetazolamide</mesh_term>
	<mesh_term>Diuretics</mesh_term>
	<mesh_term>Bumetanide</mesh_term>
	<mesh_term>Sodium Potassium Chloride Symporter Inhibitors</mesh_term>
	<criteria>Older 18 year able give inform consent Clinical diagnosis acute decompensated heart failure within previous 8 h At least two clinical sign congestion ( edema , ascites , jugular venous distension , pulmonary vascular congestion chest radiography ) Maintenance therapy oral loop diuretic dose least 1 mg bumetanide ( 1 mg bumetanide = 40 mg furosemide = 20 mg torsemide ) least 1 month hospital admission NTproBNP &gt; 1000 ng/L Left ventricular ejection fraction &lt; 50 % At least one three follow criterion : Serum sodium &lt; 136 mmol/L Serum urea/creatinine ratio &gt; 50 ( comparable BUN/creatinine ratio &gt; 25 ) Admission serum creatinine increase &gt; 0.3 mg/dL compare previous value within 3 month admission History cardiac transplantation and/or ventricular assist device Concurrent diagnosis acute coronary syndrome define typical chest pain and/or electrocardiographic change addition troponin rise &gt; 99th percentile Mean arterial blood pressure &lt; 65 mmHg , systolic blood pressure &lt; 90 mmHg moment admission Use intravenous inotropes , vasopressor nitroprusside time point study A baseline estimate glomerular filtration rate &lt; 15 mL/min/1.73m² accord Chronic Kidney Disease Epidemiology Collaboration ( CKDEPI ) formula moment inclusion Use renal replacement therapy ultrafiltration study inclusion Treatment acetazolamide within previous month Treatment ≥2 mg bumetanide equivalent dose index hospitalization randomization Use diuretic , vasopressin antagonist mineralocorticoid receptor antagonist specify protocol Exposure nephrotoxic agent ( i.e . contrast dye ) anticipate within 3 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>acetazolamide</keyword>
	<keyword>bumetanide</keyword>
	<keyword>cardio-renal syndrome</keyword>
	<keyword>diuretic</keyword>
	<keyword>heart failure</keyword>
	<keyword>natriuresis</keyword>
	<keyword>spironolactone</keyword>
</DOC>